JP2008524329A5 - - Google Patents

Download PDF

Info

Publication number
JP2008524329A5
JP2008524329A5 JP2007548319A JP2007548319A JP2008524329A5 JP 2008524329 A5 JP2008524329 A5 JP 2008524329A5 JP 2007548319 A JP2007548319 A JP 2007548319A JP 2007548319 A JP2007548319 A JP 2007548319A JP 2008524329 A5 JP2008524329 A5 JP 2008524329A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
mammal
pharmaceutically acceptable
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007548319A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008524329A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/045563 external-priority patent/WO2006068933A2/en
Publication of JP2008524329A publication Critical patent/JP2008524329A/ja
Publication of JP2008524329A5 publication Critical patent/JP2008524329A5/ja
Withdrawn legal-status Critical Current

Links

JP2007548319A 2004-12-21 2005-12-15 有糸分裂キネシン阻害剤 Withdrawn JP2008524329A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63772204P 2004-12-21 2004-12-21
PCT/US2005/045563 WO2006068933A2 (en) 2004-12-21 2005-12-15 Mitotic kinesin inhibitors

Publications (2)

Publication Number Publication Date
JP2008524329A JP2008524329A (ja) 2008-07-10
JP2008524329A5 true JP2008524329A5 (OSRAM) 2008-12-11

Family

ID=36602225

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007548319A Withdrawn JP2008524329A (ja) 2004-12-21 2005-12-15 有糸分裂キネシン阻害剤

Country Status (7)

Country Link
US (1) US20080045492A1 (OSRAM)
EP (1) EP1831176A2 (OSRAM)
JP (1) JP2008524329A (OSRAM)
CN (1) CN101084194A (OSRAM)
AU (1) AU2005319455A1 (OSRAM)
CA (1) CA2589827A1 (OSRAM)
WO (1) WO2006068933A2 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011647A2 (en) * 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin ksp
WO2008087029A1 (en) * 2007-01-17 2008-07-24 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds with acat inhibition activity
EP1950202A1 (en) * 2007-01-24 2008-07-30 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments with ACAT inhibition activity
CL2008003063A1 (es) 2007-10-19 2010-01-04 Schering Corp Compuestos derivados de 1,3,4-tiadiazol espiro condensado, inhibidores de la actividad quinesina ksp; composicion farmaceutica; y su uso en el tratamiento de enfermedades proliferativas tales como el cancer, hiperplasia, hipertrofia cardiaca, enfermedades autoinmune, trastornos fungicos, artritis, rechazo a imjertos, entre otras.
JP2011502133A (ja) * 2007-11-02 2011-01-20 メシルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害剤
WO2009094224A1 (en) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US9139589B2 (en) 2009-01-30 2015-09-22 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP2603216A4 (en) 2010-08-11 2013-12-18 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
TW201217365A (en) 2010-08-11 2012-05-01 Millennium Pharm Inc Heteroaryls and uses thereof
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
UY33671A (es) 2010-10-13 2012-04-30 Millenium Pharmaceuticals Inc Heteroarilos y sus usos
JP2014527973A (ja) * 2011-09-23 2014-10-23 バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー 非生物的な植物ストレスに対する作用剤としての4−置換1−フェニルピラゾール−3−カルボン酸誘導体の使用
WO2013096642A1 (en) * 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9828345B2 (en) 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效rock1及rock2抑制劑之苯基吡唑衍生物
CN103992274A (zh) * 2014-04-18 2014-08-20 南京安美科技有限公司 合成选择性非甾体抗炎镇痛药Celebrex(塞来昔布)的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533119A (ja) * 2002-07-17 2005-11-04 サイトキネティクス・インコーポレーテッド 化合物、組成物、及び方法
EP1773326A4 (en) * 2004-07-01 2009-07-22 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
EP1868601A4 (en) * 2005-04-07 2008-12-10 Merck & Co Inc MITOTIC KINESINE HEMMER

Similar Documents

Publication Publication Date Title
JP2008524329A5 (OSRAM)
ME00937B (me) Kombinovane terapije koje sadrže hinoksalinske inhibitore pi3k-alfa za upotrebu u liječenju kancera
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
JP2008505181A5 (OSRAM)
TW200621240A (en) Cancer treatments
CL2011001863A1 (es) Compuestos derivados de fenilaminopirimidinas, inhibidores de quinasa del linfoma anaplastico; composicion farmaceutica; combinacion farmacologica; y su uso en el tratamiento de trastornos proliferativos tales como linfoma, osteosarcoma, melanoma o tumor de mama, renal y de prostata, entre otros (divisional solicitud 3552-07).
MX2010002179A (es) Composicion para el tratamiento de enfermedades neoplasicas.
EP1951729A4 (en) OXYGEN-LINKED PYRIMIDINE DERIVATIVES
WO2007100895A3 (en) Cancer treatment with gamma-secretase inhibitors
NZ711695A (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
JP2011515481A5 (OSRAM)
IL179714A (en) Pharmaceutical preparation containing a history of 2-biphenyl-4-ram-3,2-dehydro-1h-quinazoline-4-on and its use in the preparation of cancer drugs and blood vessel formation
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
IN2012DN01964A (OSRAM)
JP2007510667A5 (OSRAM)
JP2010523696A5 (OSRAM)
WO2009046842A3 (de) Thialzolderivate zur behandlung von krebs
FR2869540B1 (fr) Compositions pharmaceutiques contenant des derives de b-carboline, et leur utilisation pour le traitement des cancers
MX2007003104A (es) Nuevos derivados de ftalazinona, como inhibidores de cinasa aurora-a.
DE602006010834D1 (de) Neue thiophensulfoximine zur behandlung von komplementvermittelten krankheiten und leiden
GEP20125603B (en) Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
NO20081292L (no) Pentasykliske kinaseinhibitorer
YU11402A (sh) Nova primena docetaksela za lečenje hepatoma
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
JP2009516719A5 (OSRAM)